Skip to main content

Table 1 Socio-demographic and clinical characteristics ( n = 734)

From: Progression of mild Alzheimer’s disease: knowledge and prediction models required for future treatment strategies

Variable

Female gender

473 (64%)

APOE ϵ4 carrier, (n = 718)

493 (69%)

Solitary living at baseline

267 (36%)

Anti-hypertensives/Cardiac therapy

290 (40%)

Anti-diabetics

38 (5%)

Lipid-lowering agents

94 (13%)

Estrogens

52 (7%)

NSAIDs/Acetylsalicylic acid

221 (30%)

Anti-depressants

183 (25%)

Anti-psychotics

26 (4%)

Anxiolytics/Sedatives/Hypnotics

111 (15%)

Variable

Mean ± standard deviation

Estimated age at onset (years)

72.3 ± 7.1

Estimated duration of AD at baseline (years)

2.9 ± 2.0

Age at first assessment (years)

75.2 ± 6.8

Education (years)

9.6 ± 2.6

MMSE score at baseline

23.4 ± 2.0

ADAS-cog score (0–70) at baseline

17.5 ± 6.7

IADL score at baseline

14.7 ± 5.0

Number of concomitant medications at baseline

2.9 ± 2.4

  1. ADAS-cog, Alzheimer’s Disease Assessment Scale-cognitive subscale; APOE, apolipoprotein E; IADL, Instrumental Activities of Daily Living scale; MMSE, Mini-Mental State Examination; NSAIDs, non-steroidal anti-inflammatory drugs.